SCHEMBL31378673

SCHEMBL31378673

COc1cc(N)cnc1N1CCN(C2COC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K12 Q12852 6/20 0.41
PIK3CA P42336 2/20 0.41
MTOR P42345 2/20 0.41
TBK1 Q9UHD2 1/20 0.37
GCK P35557 1/20 0.37
PRMT5 O14744 1/20 0.36
FGFR3 P22607 1/20 0.36
KCNH2 Q12809 1/20 0.36
OPRK1 P41145 1/20 0.36
PIK3R1 P27986 1/20 0.36
RICTOR Q6R327 1/20 0.36
RPTOR Q8N122 1/20 0.36
MAPKAP1 Q9BPZ7 1/20 0.36
MLST8 Q9BVC4 1/20 0.36
SYK P43405 1/20 0.36
LRRK2 Q5S007 1/20 0.36
TLR9 Q9NR96 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
PTK2 Q05397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20934902 0.85 OPRK1 (0.43) MAP3K12PIK3CAMTORTBK1FGFR3
SCHEMBL15243985 0.81 FGFR3 (0.52) FGFR3KCNH2LRRK2TLR9TLR7
SCHEMBL15652664 0.81 PDE10A (0.51) PIK3CAMTORLRRK2
SCHEMBL17630581 0.80 PIK3CA (0.40) MAP3K12PIK3CAMTORPRMT5KCNH2
SCHEMBL20918773 0.79 ACHE (0.50)
SCHEMBL13027673 0.79 NOS1 (0.43) GCKOPRK1LRRK2
SCHEMBL15728511 0.78 FGFR3 (0.41) FGFR3KCNH2OPRK1
SCHEMBL20935213 0.77 TRPC6 (0.47) MAP3K12PIK3CAMTORTBK1PIK3R1
SCHEMBL20934901 0.76 SLC2A1 (0.46)
SCHEMBL15540550 0.76 NR4A1 (0.46) TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-29 US disclosed
WO-2025030163-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TRHR, TSHR MAP3K12 3093/4885PIK3CA 1842/4885MTOR 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.